On Monday, Shares of XOMA Corporation (NASDAQ:XOMA), lost -12.51% to $0.82, hitting its lowest level.
XOMA Corporation declared the Phase 3 EYEGUARD-B study of gevokizumab in patients with Behcet’s disease uveitis, run by its partner Servier, an independent French pharmaceutical research company driven by the pursuit of innovative drugs, did not meet the primary endpoint of time to first acute ocular exacerbation.
“Although the study did not achieve its main objective, we did see signals of drug activity such as preserved visual acuity, less severe ocular exacerbations and a reduced incidence of stated macular edema in patients treated with gevokizumab,” said Paul Rubin MD, Senior Vice President Research and Development and Chief Medical Officer. “We will continue to work closely with our partner, Servier, and uveitis experts to conduct a thorough analysis of the data to fully understand gevokizumab’s impact on several clinically relevant endpoints.”
“The initial observations seen in the secondary endpoints are clinically important and meaningful to both clinicians and Behcet’s disease uveitis patients,” stated Dr. Ilknur Tugal-Tutkun, international coordinator for the EYEGUARD-B study and Professor of Ophthalmology, Head, Ocular Immunology and Uveitis Service at Istanbul University, Istanbul Faculty of Medicine, Department of Ophthalmology. “We look forward to learning more.”
XOMA Corporation discovers and develops antibody-based therapeutics in the United States, Europe, and the Asia Pacific. The company’s lead product candidate comprises gevokizumab, a proprietary humanized allosteric-modulating monoclonal antibody that binds to the inflammatory cytokine interleukin-1 beta, which is in Phase III clinical trial for NIU and Behçet’s disease uveitis, pyoderma gangrenosum, active non-infectious anterior scleritis, autoimmune inner ear disease, and cardiovascular diseases, in addition to diseases under the neutrophilic dermatoses designation, Schnitzler syndrome, and other diseases; and various proof-of-concept studies comprising polymyositis/dermatomyositis, Schnitzler syndrome, and giant cell arteritis.
Shares of Celgene Corporation (NASDAQ:CELG), declined -1.73% to $132.56, during its last trading session.
Celgene Corporation stated net product sales of $2,254 million for the second quarter of 2015, a 22 percent enhance from the same period in 2014. The negative net impact of currency on net product sales was 2 percent. Second quarter total revenue raised 22 percent to $2,278 million contrast to $1,873 million in the second quarter of 2014. Adjusted net income for the second quarter of 2015 raised 36 percent to $1,019 million contrast to $748 million in the second quarter of 2014. Adjusted diluted earnings per share (EPS) in the second quarter of 2015 was $1.23 which comprises a $0.06 gain related to the sale of an equity investment upon completion of their acquisition by another company. For the same period in 2014, adjusted diluted EPS was $0.90.
Based on U.S. GAAP (Generally Accepted Accounting Principles), Celgene stated second quarter of 2015 net income of $356 million or $0.43 per diluted share. For the second quarter of 2014, net income was $598 million or $0.72 per diluted share.
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases in the United States and Internationally. It markets REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma; ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers; POMALYST/IMNOVID for the treatment of multiple myeloma; and VIDAZA, a pyrimidine nucleoside analog to treat intermediate-2 and high-risk MDS, and chronic myelomonocytic leukemia, in addition to acute myeloid leukemia (AML).
Finally, TransDigm Group Incorporated (NYSE:TDG), ended its last trade with -3.42% loss, and closed at $216.93.
TransDigm Group Incorporated said it will report fiscal 2015 third quarter earnings before the market opens on Tuesday, August 4, 2015.
A conference call will follow at 11:00 a.m., Eastern Time. To join the call, dial (866) 318-8618 and enter the passcode 13576657. International callers should dial (617) 399-5137 and use the same passcode.
TransDigm Group Incorporated, through its auxiliaries, designs, produces, and supplies aerospace components for commercial and military aircraft customers in the United States. The company’s Power & Control segment develops, produces, and markets systems and components, counting mechanical/electro-mechanical actuators and controls, ignition systems and engine technology, specialized pumps and valves, power conditioning devices, and specialized AC/DC electric motors and generators.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
